SYT13 and gastric cancer: Kanda et al. constructed a mouse xenograft model with GC peritoneal metastasis and discovered that intraperitoneal administration of amido-bridged nucleic acid-modified anti-SYT13 antisense oligonucleotides could inhibit the formation of peritoneal metastatic nodules and significantly prolong survival (44).